Quarterly ResultMay 5, 2026, 04:39 PM
Adaptive Biotechnologies Q1 Revenue +35% to $70.9M; Loss Narrows
AI Summary
Adaptive Biotechnologies Corp reported a significant improvement in its financial performance for the first quarter of 2026. The company saw a substantial increase in total revenue and a notable reduction in its net loss compared to the same period last year. This positive trend was primarily driven by strong growth in MRD revenue, despite a decrease in Immune Medicine revenue following the termination of the Genentech collaboration agreement.
Key Highlights
- Total revenue increased 35.15% to $70.87 million for Q1 2026, up from $52.44 million in Q1 2025.
- Net loss narrowed to $20.02 million in Q1 2026, a 32.84% improvement from a $29.83 million net loss in Q1 2025.
- Net loss per share improved to $(0.13) for Q1 2026, compared to $(0.20) in Q1 2025.
- MRD revenue grew 53.46% to $67.09 million in Q1 2026 from $43.72 million in Q1 2025.
- Immune Medicine revenue decreased to $3.78 million in Q1 2026 from $8.72 million in Q1 2025, primarily due to the Genentech agreement termination.
- Cash and cash equivalents increased to $77.58 million as of March 31, 2026, from $70.49 million at December 31, 2025.
- The collaboration and license agreement with Genentech, Inc. was terminated, effective February 9, 2026.
Price Impact
More from ADPT